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ImmrrioN of nitric oxide synthase increases
microvascular permeability in rat small intestinal
villi. To determine the mechanism(s) whereby
this occurs we have perfused the vasculature of
rat isolated small intestines with a gelatin-con-
taining physiological salt solution. Inclusion of N-
nitrO-L-argintne methyl ester (L-NAME, 100 IM) or
indomethacin (1M) in the perfusate increased
leakage of injected colloidal carbon into micro-
vessel walls. Pre-treatment with sodium nitro-
prusside (10M) significantly reduced the effects
of both L-NAME and indomethacin, whereas car-
bacycltn (1 gM) only reduced the effects of indo-
methacin. PD151242 (1M) showed some
antagonism towards the effects of L-NAME, but
nordihydroguaiaretic acid (3ttM) was inactive.
Pre-tment with cyproheptadine (10
reduced the effects of both L-NAME and indo-
methacin, and also significantly reduced back-
ground (control) colloidal carbon leakage. Small
intestines from polymixin B-treated rats showed
significantly reduced colloidal carbon leakage in
response to L-NAME. This suggests that the
leakage-enhancing effects of both L-NAME and
indomethacin in this preparation may be
mediated by mast cell-derived amines.
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Introduction
Injured tissues release a complex mixture of
pro- and anti-inflammatory compounds. Several
authors have shown recently, for example, that
endogenous nitric oxide (NO) can protect rat
small intestine/mesentery preparations that are
injured, resulting in less increase in microvascular
permeability to either albumina-5 or colloidal
carbon,
6 or net fluid secretion into the intestinal
lumen.7 Microvascular leakage is generally
thought to occur because of a loss of endothelial
integrity, resulting from endothelial cell contrac-
tion.
8 Thus, endothelial cell relaxation in
response to NO would be expected to bring
about a recovery of this integriW. Therefore, just
as vascular smooth muscles are known to relax
in response to NO,9 as a result of activation of
guanylyl cyclase,
1 so too might endothelial cells.6
Prostacyclin and certain other prostanoids can
also bring about vascular relaxation,9 and their
release from endothelial cells concomitantly with
NO has been demonstrated to occur in response
to inflammatory stimuli in vivo,
-13 in isolated
vessels14’5 and in cultured cells.6-8 Endothelin
may also be released concomitantly with NO
under these circumstances.17’19 In addition, it has
been suggested that normality in the intestinal
vasculature is maintained by a balance between
the opposing effects of secreted NO and various
5-1ipoxygenase products,
i
Ischaemia-reperfusion injury in rat small intes-
tine causes a degranulation of mucosal mast
cells.2’2 Furthermore, mast cells release an NO-
like factor which can in turn modulate the
release of pro-inflammatory mediators.
22 Partici-
pation of mast cells in other forms of intestinal
injury, however, is poorly understood.
In the present work we have attempted to cor-
relate these various findings and suggestions
using a rat isolated perfused small intestine/
mesentery preparation, with injected colloidal
carbon acting as a marker of increased micro-
vascular permeability.
Materials and Methods
Preparation ofsmall intestine: The basic method
has been described in detail previously.
23 Briefly,
rats weighing 350-500g were killed by inhalation
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of chloroform vapour. Immediately thereafter, a
cannula was placed in the anterior mesenteric
artery. The small intestine, with its accompanying
blood vessels, was then ligated at its caecal and
pyloric ends. Along with its mesentery, the intes-
tine was next removed to an isolated-organ bath
containing perfusate. The cannula was then con-
nected to a reservoir of the same perfusate main-
tained at 37c.
Perfusion protocols: With perfusate flowing at
10ml/min the vasculamre was first cleared of
residual blood. The perfusate, with test drugs
added as appropriate, was then re-circulated
through the tissue for 17 min. Then 0.5 ml colloi-
dal carbon suspension was introduced into the
perfusion line near the cannula. The perfusate
was thereafter allowed to run to waste for 8 min,
using fresh perfusate for the last 6 min, and
increasing the flow rate to 20 ml/min for the final
2 min to ensure removal of the last traces of col-
loidal carbon from the vessel lumens. Finally,
2 ml rat washed red blood cells were introduced
near the cannula to provide a visual check for
patency of the microvessels when the tissue was
examined microscopically at the end of the
experiment.
Image analysis: The small intestine was next
removed from the organ bath to a tray contain-
ing normal saline. Starting at the caecal end, six
segments, each approximately 4cm in .length,
were cut. Each segment was flushed with normal
saline, opened lengthwise along its mesenteric
border and stapled to a xylene-resistant plastic
coverslip. After fixation, dehydration, and a
period of clearance in xylene, the specimens
were mounted, mucosal surface uppermost, in
DPX mountant on glass slides. Micrographs of
villous microvessels in five widely separated areas
of each specimen were taken at x 100 magnifica-
tion. Negative micrographs were subjected to
image analysis, and areas depicting colloidal
carbon deposits in each field were expressed as
a percentage of the frame (negative micrograph)
area, as described earlier.23
Perfusates: The basic perfusate used was a phy-
siological salt solution containing gelatin and had
the following composition (mM): NaC1, 138; KCl,
5; NaHCO3, 10.1; MgCI2, 1.06; NaH2PO4, 0.416;
Gag12, 2; glucose, 10; plus 2% gelatin, giving pH
7.4. It was gassed throughout with 95% O2 and
5% CO2 in both the organ bath and the reser-
voir.
In the first series of experiments those drugs
to be tested as possible antagonists of colloidal
carbon leakage were added to 50 ml of perfusate
at the beginning of the 17 min re-circulation
period, followed 2 min later, where appropriate,
by addition of drugs that were being tested as
possible promoters of colloidal carbon leakage.
In a second series of experiments those drugs
being tested as possible antagonists were added
to the perfusate from the outset, and thus were
present even while flushing blood from the vas-
culature. Drugs being tested as agonists,
however, were added only for the 15 min re-
circulation period.
In a third series of experiments rats were
injected i.p. with a single dose of 10000 units of
polymixin B 3 days prior to being used to
provide tissue for in vitro perfusion. Polymixin B
at this dose was reported to deplete rat mast
cells of stored amines.
’4
Chemicals: N-nitro-L-arginine methyl ester (L-
NAME, 100/.tM) and indomethacin (1 I.tM) were
tested as possible agonists. Sodium nitroprusside
(10btM), carbacyclin (1 btM), cyproheptadine HCl
(10tM), nordihydroguaiaretic acid (31.tM) and
PD151252 (1 I.tM) were tested as possible
antagonists. L-NAME, indomethacin, sodium nitro-
prusside, cyproheptadine, PD151242 and poly-
mixin B were used as aqueous solutions.
Carbacyclin was dissolved first in ethanol, and
nordihydroguaiaretic acid in dimethylsulphoxide.
A dose-volume of 0.2 ml was added to 50ml of
perfusate in the reservoir.
L-NAME, carbacyclin, nordihydroguaiaretic acid
and polymixin B were purchased from Sigma
Chemical Co. (Poole, UK); sodium nitroprusside
from David Bull Laboratories (Warwick, UK);
indomethacin and cyproheptadine from Merck,
Sharpe & Dohme Ltd (Hoddesdon, UK).
PD151242 was a gift from Dr A. Doherty, Parke
Davis (Ann Arbor, MI, USA). Gelatin and DPX
mountant were obtained from BDH (Poole, UK);
Thermanox(R) xylene-resistant coverslips from
Nunc Inc. (Naperville, IL, USA) and colloidal
carbon (Gunther Wagner, Batch C11/1431a)
from Pelikan Inks (Hanover, Germany).
Statistics: Bonferroni’s test was used for com-
paring multiple groups with a single control
group.
Results
Effects ofL-NAME and indometbacin on colloidal
carbon leakage_: L-NAME (100 l.tM), an NO syn-
25 thase inhibitor, increased the leakage of colloi-
dal carbon into villous microvessel walls (Table
1), confirming earlier work.6 Indomethacin
(1 l.tM), a cyclooxygenase inhibitor,
z6 also
increased colloidal carbon leakage (Table 1).
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Table 1. Effects on colloidal carbon leakage in rat small intestinal villous microvessels of adding L-NAME or indomethacin
(Indo) to the perfusate for 15 min after pre-treatment with various agents for 2 min
Treatment Amount of CC leakage (as % of frame areaS)
b
n GPSS n GPSS + L-NAME n GPSS + Indo
Control 17 0.99 + 0.12 10 2.54 + 0.30 10 2.19 + 0.23cc’d
SNP ND ND 10 1.37 + 0.19
dd
Carbacyclin 4 0.91 + 0.22 6 2.30 + 0.31 6 1.10 + 0.24
dd
NDGA 4 1.28 + 0.23 6 2.04 + 0.41 ND
PD151242 ND 6 1.70 __+ 0.23 ND
Cypro 6 0.32 + 0.08 ND ND
aEach frame represents one negative micrograph magnified approximately 20 times, bValues are given as mean + S.E.M. There are
significant differences (p < 0.05, Bonferroni’s test) between groups marked and cc; between groups marked and dd; and between
groups marked and "e. ND Not done.
Abbreviations not used in text: GPSS gelatin-containing physiological salt solution; SNP sodium nitroprusside; NDGA
nordihydroguaiaretic acid; Cypro cyproheptadine. Concentrations of L-NAME, indomethacin, SNP, carbacyclin, NDGA, PD151242 and
cyproheptadine are given in the Methods section.
Effects of adding sodium nitroprusside, carbacy-
clin, PD151242, nordihydroguaiaretic acid or
cyproheptadine to the perfusate 2 min prior to L-
NAME or indomethacin: Sodium nitroprusside
(10 I.tM), an NO donor,
27 has been shown earlier
to significantly reduce the t-NAME-induced
leakage of colloidal carbon in this preparation.
6
In the present work it also reduced the indo-
methacin-induced colloidal carbon leakage
(Table 1). In contrast, pre-treatment with carba-
cyclin (1 gM), a less rapidly metabolized, syn-
thetic analogue of prostacyclin,
8 significantly
reduced the indomethacin-induced colloidal
carbon leakage but had no effect on the leakage-
response to t-NAME (Table 1). PD151242
(1 gM), an endothelinA-receptor antagonist,9
showed a trend towards reducing the t-NAME-
induced colloidal carbon leakage, but nordihy-
droguaiaretic acid (3 gM), a 5-1ipoxygenase inhi-
bitor,
3 had no discernible effect (Table 1). None
of the above named putative antagonists had any
effect on the control (background) colloidal
carbon leakage (Table 1). In contrast, addition to
the perfusate of cyproheptadine (10gM), a
mixed histamine and 5-hydroxytryptamine recep-
tor antagonist,
3 significantly reduced control
(background) colloidal carbon leakage (Table 1).
Effects of using perfusate containing sodium
nitroprusside, carbacyclin or cyproheptadine
throughout on the responses to L-NAME or indo-
methacin: In agreement with the foregoing
results, the continuous presence of cyprohepta-
dine also significantly reduced control (back-
ground) colloidal carbon leakage (Table 2),
whereas the continuous presence of sodium
nitroprusside and carbacyclin, although tending
now to reduce the background leakage of colloi-
dal carbon, still failed to show a statistically sig-
nifican effect (p< 0.175, Bonferroni’s test for
carbacyclin, whereas p< 0.025 Student t-test)
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(Table 2). Cyproheptadine also completely pre-
vented both the L-NAME- and the indomethacin-
induced leakage of colloidal carbon, reducing
them to the same low value that was seen with
cyproheptadine alone (Table 2).
Effects ofpre-treatment with polymixin B: There
was a significant reduction in colloidal carbon
leakage in the L-NAME-treated group of prepara-
tions from rats pre-treated with polymixin B
when compared with rats not so pre-treated
(Table 2). However, there was no significant dif-
ference between rats pre-treated with polymixin
B and those in the control group (Table 2).
Discussion
In the present experiments both L-NAME and
indomethacin significantly increased the leakage
of colloidal carbon over and above control
(background) values in rat villous microvessels
(Table 1), suggesting that the release of both NO
and a cyclooxygenase product contributed to
endothelial integrity under these perfusion condi-
tions. This interpretation is supported by the fact
that pre-treatment with sodium nitropmsside
reduced the leakage of colloidal carbon caused
by both L-NAME and indomethacin. Carbacyclin,
on the other hand, overcame the leakage-pro-
moting effect of indomethacin but not that of L-
NAME (Table 1). This suggests that the protec-
tive effects of exogenous carbacTclin, and hence
probably of endogenous prostacyclin-like sub-
stances, occurred indirectly by increasing the
availability of NO in the intestinal mucosa. They
would not.be expected to exert an effect, there-
fore, in the absence of NO synthase activity
resulting from the presence of L-NAME. Interac-
tions between the NO-synthase and cycloox-
ygenase pathways, however, seem to vary in
different parts of the body. Thus, in some tissuesNO synthase inhibition and mast cells
NO can release prostacyclin rather than vice
versa. It has been shown, for example,32’33 that
the cyclooxygenase activity of macrophages in
vitro can be increased either by enhancement of
NO synthase activity or by treatment with an NO
donor such as sodium nitroprusside. In. contrast,
exogenously applied prostacyclin was shown to
release NO in pig pial arteries in vivo.34 Reasons
for these tissue differences remain to be
explored.
5-Lipoxygenase is another enzyme that is
involved in arachidonic acid metabolism, but it
did not appear to be involved in the present
experimental situation, since nordihydroguaiaretic
acid failed to reduce the leakage-producing
effects of t-NAME (Table 1). This contrasts with
the report that BW A137C, another 5-1ipoxy-
genase inhibitor,3 can protect rat colonic micro-
vessels against the permeability-enhancing effects
of L-NAME.
2 However, the latter experiments
were carried out in vivo, and with lipopoly-
saccharide co-administered to enhance the
effects of L-NAME. In contrast, the present
experiments were performed in vitro, and
without augmentation of the actions of t-NAME.
Which of these several experimental differences
is responsible for the differing results obtained is
not known, but it cautions against any simplistic
extrapolation of the present findings to in vivo
situations.
Rats injected i.v. with t-NAME have been
reported to show modest increases in the plasma
levels of endothelin-1.5 Similarly, in the present
experiments there was no significant reduction
(Bonferroni’s test) in the t-NAME-induced colloi-
dal carbon leakage in vitro after pre-treatment
with PD151242 (Table 1), although the reduction
showed some significance after applying a
Student t-test (p < 0.05). We have reported pre-
viously that exogenously applied endothelin-1
increases collodial carbon leakage in this pre-
paration to some extent, but it is much more
potent as a vasoconstrictor.36
Mast cell degranulation is known to be
involved in ischaemia-reperfusion injury in the
rat small intestine.2’21 Moreover, Table 1 shows a
reduction in background colloidal carbon
leakage as a result of pre-treatment with cypro-
heptadine. Furthermore, Table 2 shows that col-
loidal carbon leakage is reduced to the same very
low level by treatment with cyproheptadine both
in the absence and presence of either L-NAME or
indomethacin. This suggests that mast cell-
derived histamine and/or 5-hydroxytryptamine
mediate part of the colloidal carbon leakage seen
in the controls, as well as the increased leakage
shown by tissues exposed to t-NAME or indo-
methacin. It is particularly significant, therefore,
that the small intestine/mesentery preparations
derived from rats pre-treated with polymixin B,
in order to deplete the mast cell stores of
amines,24’3 also showed very little colloidal
carbon leakage in response to L-NAME. All these
results point to mast cell-derived amines control-
ling microvascular permeability in this prepara-
tion, and it may be that these amines perform
the same function as lipopolysaccharide in
vivo.’4 Mast cell-derived mediators have been
shown previously to be involved in the t-NAME-
induced epithelial permeability enhancement
seen in rat small intestine in vivo.37 Since mast
cells are also thought to secrete NO, and since
this NO may actually stabilize those same cells
which manufacture it,
22 experiments were per-
formed in which sodium nitroprusside was
added to the perfusate from the outset in order
to mimic and augment the actions of endogen-
ous NO. Background colloidal carbon leakage
Table 2. Effects on colloidal carbon leakage of perfusing rat small intestinal villous
microvessels with gelatin-containing physiological salt solution (GPSS) containing various
agents from the start of perfusion, or of pre-treating rats in vivo with polymixin B (PMX-B)
72 h prior to perfusion in vitro
Perfusate Treatment n Amount of CC leakage
(as % of frame areaa)
b
GPSS + Cypro 7 0.28 ___
0.08
GPSS + Cypro L-NAME* 5 0.29 ___
0.09
d
GPSS + Cypro Indomethacin* 5 0.33 -t- 0.12
GPSS + SNP 5 0.67 -I-0.04
GPSS + Carbacyclin 4 0.38 0.10
GPSS PMX-B 6 0.67 +__ 0.12
GPSS PMX-B + L-NAME* 5 0.89 -t- 0.37
d
*L-NAME or indomethacin added for 15 min only. aEach frame represents one negative micrograph
magnified 20 times, bValues are given as mean ___
S.E.M. Cp < 0.05 (Bonferroni’s test) compared with
GPSS control value in Table 1; dp < 0.05 (Bonferroni’s test) compared with GPSS + L-NAME value in Table
1; ap < 0.05 (Bonferroni’s test) compared with GPSS + Indo value in Table 1. Abbreviations not used in
text: Cypro cyproheptadine; SNP sodium nitroprusside. Concentrations of Cypro, SNP, Carbacyclin, L-
NAME and indomethacin are given in the Methods section.
Mediators of Inflammation Vol 5 1996 35A M. Northover and B. J. Northover
was reduced by sodium nitroprusside, but not
significantly so, suggesting that perhaps endogen-
ous NO is more effective in this respect than the
NO derived from sodium nitroprusside. If so, the
greater effectiveness of carbacyclin over sodium
nitroprusside on background colloidal carbon
leakage may have been because carbacyclin acts
by releasing endogenous NO, as suggested
earlier.
The main conclusion to be drawn from the
present work, therefore, is that some mast cell
secretion occurs during perfusion of the rat
intestinal vasculature with gelatin-containing phy-
siological salt solution in vitro. Vascular leakage
caused by this secretion is exacerbated by
including either L-NAME or indomethacin in the
perfusate, suggesting that NO and a prostanoid
normally operate to restrain vascular perme-
ability. It is uncertain whether this protection is
due to prevention of the release of mast cell
amines or an inhibition of their vascular effects.
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